News Headlines

31. Rentschler Biopharma Further Expands Its Services In Japan And South Korea And Will Attend Bioprocess International Asia 10/6/2025

    Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is highlighting its flexible and optimized solutions for the development and manufacture of a wide range of biologics for clients in Japan and South Korea.

32. XenoSTART And Minerva Imaging Expand Partnership To Deliver Integrated PDX-Radiopharmaceutical Drug Development Platform 10/2/2025

    The START Center for Cancer Research ("START"), its preclinical division XenoSTART, and Minerva Imaging today announced an expansion of their decade-long partnership to establish the industry's most comprehensive integrated platform for radiopharmaceutical drug development.

33. tcmc Highlights CAR-T Innovation At BioJapan 2025, Catalyzing Taiwan-Japan Cancer Cell Therapy Partnerships 10/1/2025

    Taiwan Cell Manufacturing Company (tcmc), a state-of-the-art CDMO specializing in cell and gene therapy (CGT) manufacturing, is participating in BioJapan 2025 - Asia's premier biotechnology exhibition – taking place October 8-10 in Yokohama, Japan.

34. Cell Therapies And Teijin Announce Strategic Collaboration To Expand Access To Advanced Cell And Gene Therapies In Japan And The Asia Pacific Region 10/1/2025

    Cell Therapies Pty Ltd. (“Cell Therapies”) and Teijin Limited announced today that they have signed a Memorandum of Understanding (MoU) to strengthen regional infrastructure for cell and gene therapies (CGT), leveraging advanced GMP capabilities and cross-border collaboration to accelerate development and improve patient access across Japan and the wider Asia Pacific region.

35. OmniaBio Inc. And BrainChild Bio Announce Collaboration To Accelerate CAR-T Cell Therapy Development In Brain Cancer 10/1/2025

    OmniaBio Inc., a next generation contract development and manufacturing organization (CDMO) pioneering the manufacturing of cell and gene therapies (CGT) with robotics and artificial intelligence, and BrainChild Bio Inc, a clinical-stage biotechnology company developing Chimeric Antigen Receptor T-cell (CAR-T) therapies to treat solid tumors in the central nervous system, today announced their collaboration aimed at manufacturing BrainChild Bio's pivotal clinical trial therapeutic candidate BCB-276.

36. Symbiosis Expands Sterile Manufacturing Capacity With Fill/Finish Line Qualification 9/30/2025

    Symbiosis has successfully completed qualification of its new FPD 50 Flexicon automated fill/finish line at its new commercial production facility in Stirling, Scotland.

37. Made Scientific And Syenex Forge Technology Partnership To Transform T Cell Therapy Manufacturing 9/30/2025

    Made Scientific, a leading cell therapy contract development and manufacturing organization (CDMO) and Syenex, a synthetic biology company specializing in best-in-class targeted delivery technologies, today announced a technology partnership to advance the scalability and efficiency of engineered T cell therapies through the use of Syenex's bioengineering systems, UltraCell™ and RapidCell™, providing improvement in gene delivery efficiency and engineering timelines.

38. Hinge Bio Announces License And Collaboration With Kyorin Pharmaceutical Co., Ltd. For The Development And Commercialization Of HB2198 In Japan For Autoimmune Diseases 9/30/2025

    Hinge Bio, Inc., a privately-held biotechnology company engaged in the discovery and development of innovative medicines, announced it has entered into a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd (“Kyorin”) for development of Hinge Bio’s multispecific antibody-based therapeutic HB2198 in Japan for multiple autoimmune indications, starting with Systemic Lupus Erythematosus (“SLE”).

39. Bora Pharmaceuticals Introduces High-Potency Liquid Capsule Technology In Taiwan 9/30/2025

    Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing, has announced the addition of liquid-filled hard capsule (LFC) production capabilities at its Zhunan, Taiwan facility.

40. Bionique Testing Laboratories Strengthens Operations With ~35,000 Sq Ft Expansion To Further Support Drug Development And Demand For Rapid Biosafety Testing Solutions 9/30/2025

    Bionique Testing Laboratories LLC (Bionique), a subsidiary of Asahi Kasei and a globally recognized mycoplasma testing services specialist for the life science industry, hosted a Grand Opening Ceremony on September 26th to commemorate the completion of its newly expanded facility.